Shares of minimally invasive therapeutic ultrasonic technologies and regenerative medicine provider Misonix, Inc. (MSON) are up more than 11% Friday morning at $26.45.
Thursday the company announced its decision to be bought by Bioventus Inc. (BVS) in a cash-and-stock transaction valued about $518 million.
As per the deal, Misonix stockholders can choose to receive either 1.6839 shares of Bioventus class A common stock or $28 in cash, for each Misonix share they hold.
The transaction is expected to close in the fourth quarter of 2021.
MSON touched a new high of $26.86 this morning.
For comments and feedback contact: editorial@rttnews.com
Get Access to Premium Stock Alerts with RTT Intelligent Investor.
